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~-Acetyl-L-glutamate synthetase catalyzes the synthesis of ~a~etyl-L-glutamate, an allosteric and 
essential activator of carbamoyi-phosphate synthetase I in the liver of ureotelic animab. The enzyme is 
activated specifically by arginine. We report here that the sensitivity of the synthetase to activation by 
arginine increases markedly after intraperitoneal administration to mice of inhibitors of nucleic acid and 
protein synthesis, including actinomycin D, aurintricarboxylic acid, cycloheximide, emetine and 
puromycin. The effects of cycloheximide were investigated in detail and an amino acid analysis was made 
of the homogenate of freeze-clamped livers of control or cy~loheximide-treated mice. 
Mitochondria Urea synthesis Acetylglutamate synthetase Arginine 
Cycloheximide Carbamoyl-phosphate synthetase I 
1 o INTRODUCTION 
We have proposed [l-5] that N-acetyl-L-gluta- 
mate, a specific and obligatory allosteric activator 
of mitochondrial carbamoyl-phosphate synthetase 
I (EC 6.3.4.16) [6,7], participates in the control of 
urea biosynthesis in the liver of ureotelic animals, 
through the mediation of its hepatic level. The con- 
trol mechanism has been supported by findings of 
several other research groups [8-131 (review [14]). 
We first obtained evidence for the presence of 
acetylglutamate synthetase (EC 2.3.1.1) [ 151, the 
enzyme which catalyzes the formation of acetylglu- 
tamate from glutamate and acetyl-CoA, in mito- 
chondria of mammalian liver. The enzyme was 
partially purified from rat liver [16,17] and from 
human liver [ 181. A unique property of this enzyme 
is the activation by arginine. In [19] the sensitivity 
of the synthetase to activation by arginine under- 
went marked changes after ingestion of food; these 
changes appeared to be due to a modification of 
the enzyme molecule itself [19]. 
We now report that the sensitivity of the syn- 
thetase to arginine activation increases markedly 
after intraperitoneal administration of inhibitors 
of nucleic acid and protein synthesis, irrespective 
of dietary conditions. 
2. MATERIALS AND METHODS 
* To whom correspondence should be addressed 
Abbreviation: acetylgiutamate, N-acetyl-L-glutamate 
Male dd/Y strain mice, 5-6 weeks old, 15-20 g 
body wt, were used throughout. Ammonium 
aurintricarboxylate, cycloheximide and 
emetine -HCl were obtained from Nakarai 
Chemicals (Kyoto). Actinomycin D and 
puromycin ~2 HCl were from Makor Chemicals 
(Jerusalem) and American Cyanamid (New York), 
respectively. 
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Acetylglutamate synthetase in the sonicated 
mitochondria was measured, as in [19], except that 
the isolated mitochondria were suspended in 
50 mM potassium phosphate buffer (pH 7.2) con- 
taining 0.5 mM dithiothreitol. Protein was deter- 
mined as in [ 191. 
Determination of amino acids in the liver was 
carried out as follows. Livers were freeze-clamped, 
powdered and homogenized with 5 vol. 1 M per- 
chloric acid in a Polytron homogenizer 
(Kinematica GmbH, Luzern). The extract and the 
washings of the residue were combined and then 
analyzed using a Hitachi amino acid analyzer, 
model 835 (Hitachi, Tokyo). 
3. RESULTS 
Various inhibitors of nucleic acid and protein 
synthesis were given intraperitoneally to fasted 
mice and the activity and arginine sensitivity of 
Table 1 
Changes in activity of acetylglutamate synthetase after 
treatment of mice with inhibitors of nucleic acid and 
protein synthesis 
Treatment Acetylglutamate Activa- 
synthetase activity tion by 
(nmol . h-r. mg arginine 
protein-‘) (-fold) 
- Arg + Arg 
Control 0.13 0.21 1.6 
Actinomycin D 0.31 1.11 3.6 
Aurintricarboxylate 0.51 3.38 6.6 
Cycloheximide 0.33 2.95 8.9 
Emetine 0.71 4.47 6.3 
Puromycin 0.37 3.44 9.3 
Six groups of 3 mice each were fed the usual laboratory 
chow for 3 h (from 9.00 pm-12.00 pm) for 3 days and 
were then fasted for 33 h and given actinomycin D, 
cycloheximide or emetine (1, 50 or 5 pg/g body wt, 
respectively) after 0, 3 and 6 h, aurintricarboxylate or 
puromycin (3 or 75 pg/g body wt, respectively) at each 
hour. Control mice were given only 0.15 M NaCl after 
0, 3 and 6 h. All mice were killed after 8 h and 
mitochondria were isolated from the pooled 3 livers, 
suspended and sonicated. The enzyme activity was 
measured in the presence and absence of 
1 mM L-arginine 
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acetylglutamate synthetase were examined after 
8 h (table 1). When mice were given 0.15 M NaCl 
(control mice), the activities both in the presence 
and absence of arginine (1 mM) were low, and the 
extent of arginine activation was 1.6. On the con- 
trary, when mice were given inhibitors of protein 
synthesis, including aurintricarboxylate, cyclo- 
heximide, emetine and puromycin, the activity in 
the absence of arginine increased several times, 
whereas the activity in the presence of arginine in- 
creased to a remarkably greater extent (> 15-fold). 
As a consequence, the extent of arginine activation 
increased 6-9-fold. When mice were treated with 
actinomycin D, an inhibitor of ribonucleic acid 
synthesis, the extent of arginine activation remain- 
ed as low as 3.6-fold. 
Of the 5 inhibitors of nucleic acid and protein 
synthesis, effects of cycloheximide were in- 
- arginine 
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Time (h) 
Fig. 1. Changes in acetylglutamate synthetase activity 
during the course of cycloheximide treatment of mice. A 
total of 12 mice were fed and fasted as in table 1. On day 
5, 3 animals were killed at O-time. The other animals 
were given cycloheximide (5Opg/g body wt) at 3-h 
intervals as indicated by the arrows. Three mice were 
killed every 4 h. The enzyme activity in the sonicated 
liver mitochondria was measured in the presence (0) 
and absence (0) of 1 mM L-arginine as in table 1. 
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vestigated in greater detail. When the agent 
(5O/cg/g body wt) was repeatedly given to fasted 
mice at 3-h intervals, the activity in the absence of 
arginine remained at similar levels throughout the 
entire period of 12 h (fig.1). The activity in the 
presence of arginine increased remarkably with 
time, and there was a marked increase in the extent 
of arginine activation. Dose response of the syn- 
thetase activity to cycloheximide is illustrated in 
fig.2. Mice were given various doses (0, 10, 20, 50, 
100 or 200 pg/g body wt) of cycloheximide 3-times 
at 3-h intervals and the hepatic enzyme activity was 
examined after 8 h. The activity assayed in the 
absence of arginine did not significantly change, 
while the activity assayed in the presence of 
arginine increased with increasing doses up to 
about 20 pg/g body wt for a single injection. The 
I I 
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Fig.2. Dose response of acetylglutamate synthetase 
activity to cycloheximide. Six groups of 3 animals were 
fed and fasted as in table 1. On day 5, cycloheximide (0, 
10, 20, 50, 100 or 200 pg/g body wt) was given to mice 
after 0, 3 and 6 h. All mice were killed after 8 h and the 
enzyme activity in the sonicated liver mitochondria was 
measured in the presence (0) and absence (0) of 1 mM 
L-arginine as in table 1. 
maximal arginine activation ratio attained by treat- 
ment with cycloheximide was 8-11-fold when the 
dose was over 20 kig/g body wt. When liver slices 
were incubated with [35S]methionine, the incor- 
poration of radioactivity into the trichloroacetic 
acid-insoluble fraction of 7500 x g precipitate or 
supernatant of liver homogenate from the 
antibiotic-treated mice was only 7-9070 of that 
from control mice (not shown). The hepatic pro- 
tein synthesis of cycloheximide-treated mice ap- 
pears to be strongly repressed. 
Content of each amino acid in the homogenate 
of freeze-clamped livers of control or cyclohexi- 
mide-treated mice was measured (table 2). The 
hepatic levels of some amino acids, including 
citrulline, valine, isoleucine, leucine, tyrosine, 
lysine and arginine, in the treated mice were higher 
than in the controls, while the levels of some amino 
acids, including glutamic acid, glycine, 
phenylalanine and histidine, were lower. The total 
amount of amino acids in the livers of the treated 
mice was about 110% of that of the control mice. 
4. DISCUSSION 
Factors known to be involved in the control of 
acetylglutamate synthetase activity are the intra- 
cellular levels of glutamate and acetyl-CoA [3], 
substrates, the concentrations of competitive in- 
hibitors, such as propionyl-CoA [20], the hepatic 
content of arginine [3], a specific activator of the 
synthetase and the changes in sensitivity of the syn- 
thetase to arginine activation [ 191. It was also 
found [19] that cycloheximide injection, which in- 
hibited the total protein synthesis in the mouse 
liver by 90070, did not inhibit the postprandial in- 
crease in arginine activation of the synthetase, thus 
indicating that the protein synthesis is not required 
for the change; actually cycloheximide stimulated 
the increase to a significant extent. Here, we 
demonstrated that arginine sensitivity of the syn- 
thetase increased markedly after injection of in- 
hibitors of protein synthesis, including aurintri- 
carboxylate, cycloheximide, emetine and 
puromycin, irrespective of dietary conditions 
(table 1). With actinomycin D, an inhibitor of 
DNA-dependent RNA synthesis, there was a 
smaller increase in arginine sensitivity, probably 
due to delay in the cessation of protein synthesis. 
Regardless of the same or different mechanisms by 
119 
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Table 2 
Effects of cycloheximide on hepatic amino acid levels in mice 
Amino acid Control mice Treated mice 
Taurine 
Aspartic acid 
Threonine 
Serine 
Glutamic acid 
Glutamine 
Glycine 
Alanine 
Citrulline 
Valine 
Methionine 
Isoleucine 
Leucine 
Tyrosine 
Phenylalanine 
Ornithine 
Lysine 
Histidine 
Arginine 
(pmo1.g liver-‘) 
15.93 + 1.38 
2.54 f 0.19 
0.41 f 0.08 
0.52 f 0.15 
1.61 + 0.44 
2.77 f 0.65 
1.51 + 0.19 
0.58 + 0.53 
0.34 f 0.29 
0.40 f 0.14 
0.09 rt 0.02 
0.20 f 0.05 
0.32 f 0.06 
0.04 + 0.03 
0.09 * 0.01 
0.85 + 0.12 
0.66 + 0.26 
0.48 f 0.08 
0.03 + 0.04 
(pmo1.g liver-‘) (070 control) 
18.06 * 0.77 113 
2.13 + 0.36 84 
0.57 + 0.05 139 
0.69 + 0.06 133 
0.89 f 0.14 55 
3.91 f 0.24 141 
0.98 f 0.08 65 
0.42 f 0.20 72 
0.88 f 0.44 259 
0.64 f 0.05 160 
0.10 f 0.00 111 
0.30 f 0.04 150 
0.48 + 0.04 150 
0.06 + 0.01 150 
0.05 * 0.01 56 
0.69 + 0.07 81 
1.33 * 0.33 202 
0.30 + 0.09 63 
0.13 + 0.03 433 
Total 29.35 f 0.95 32.56 + 0.16 111 
A total of 7 mice were fed and fasted as in table 1. On day 5, 4 mice were given 
cycloheximide (50 ,ug/g body wt) after 0, 3 and 6 h. Control animals were given 
0.15 M NaCl. All mice were killed after 8 h and analysis of amino acids in the liver 
was done as described in section 2. Values represent the mean value * SD (3 
control, and 4 treated animals) 
which the inhibitors bring about the increase in 
arginine sensitivity of the synthetase and by which 
diet causes similar changes, the increases induced 
by these inhibitors will aid in elucidating postpran- 
dial changes. Inhibition of synthesis of protein fac- 
tor(s), with a short half-life, may produce increases 
in arginine sensitivity of the synthetase, following 
administration of cycloheximide to mice. 
Table 2 shows that the hepatic level of total 
amino acids of cycl6heximide-treated mice increas- 
ed to some extent, in comparison to levels seen in 
control mice, and that the level of some amino 
acids increased significantly in the treated mice. 
How these changes relate to increases in arginine 
sensitivity is the subject of ongoing investigation in 
our laboratory. 
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